{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:03:34Z","timestamp":1790870614719,"version":"4.1.0"},"reference-count":12,"publisher":"S. Karger AG","issue":"2-3","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dement Geriatr Cogn Disord"],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background\/Aims:&lt;\/i&gt;&lt;\/b&gt; A large multicenter trial of donepezil 23 mg\/day versus donepezil 10 mg\/day for moderate-to-severe Alzheimer\u2019s disease allowed patients taking concomitant memantine. We evaluated the efficacy\/safety of donepezil 23 and 10 mg\/day in this trial, with respect to concomitant memantine use. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Prespecified analysis of data from a 24-week, randomized, double-blind trial. Patients were randomized to donepezil doses (23 vs. 10 mg\/day) and stratified by concomitant memantine use (yes or no). Efficacy and safety were assessed for each donepezil dose in subgroups taking or not taking concomitant memantine. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; At week 24, donepezil 23 mg\/day provided significant cognitive benefits over 10 mg\/day (p &lt; 0.01) on the Severe Impairment Battery, with or without concomitant memantine (ANCOVA adjusted for baseline score, country and treatment). The higher dose showed no benefit on the global function, Mini-Mental State Examination or activities of daily living measures in either memantine subgroup. Rates of treatment-emergent adverse events (AEs) were higher for donepezil 23 mg\/day with memantine (80.7%) than 23 mg\/day without memantine (69.7%) or 10 mg\/day with\/without memantine (66.7\/62.0%); across all treatment groups, most events were mild\/moderate in severity. Individual rates of serious AEs were low (&lt;1.0%), regardless of concomitant memantine use. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; In this population, concomitant memantine use did not alter the response profile of donepezil 23 vs. 10 mg\/day. Donepezil 23 mg was generally safe and well tolerated among patients receiving donepezil alone and among patients receiving a combination of donepezil and memantine therapy.<\/jats:p>","DOI":"10.1159\/000338236","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T10:36:21Z","timestamp":1336646181000},"page":"164-173","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer\u2019s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine"],"prefix":"10.1159","volume":"33","author":[{"given":"Rachelle S.","family":"Doody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Geldmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Farlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Moline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Mackell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2012,5,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159%2F000122962"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159%2F000098052"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1345%2Faph.1D638"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001%2Fjama.291.3.317"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212%2F01.wnl.0000223333.42368.f1"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097%2F01.wad.0000213859.35355.59"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097%2F01.wad.0000213860.35355.d4"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097%2FWAD.0b013e31816653bc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136%2Fjnnp.2008.158964"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.clinthera.2010.06.019"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2FS0304-3940%2801%2901872-9"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1634%2Ftheoncologist.7-5-424"}],"container-title":["Dementia and Geriatric Cognitive Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/338236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/338236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:17:38Z","timestamp":1745417858000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000338236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":12,"journal-issue":{"issue":"2-3","published-online":{"date-parts":[[2012,6,1]]},"published-print":{"date-parts":[[2012,6,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000338236","archive":["Portico"],"relation":{},"ISSN":["1420-8008","1421-9824"],"issn-type":[{"value":"1420-8008","type":"print"},{"value":"1421-9824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}